Nature Communications (Feb 2022)
Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications
- Maryam A. Y. Al-Nesf,
- Houari B. Abdesselem,
- Ilham Bensmail,
- Shahd Ibrahim,
- Walaa A. H. Saeed,
- Sara S. I. Mohammed,
- Almurtada Razok,
- Hashim Alhussain,
- Reham M. A. Aly,
- Muna Al Maslamani,
- Khalid Ouararhni,
- Mohamad Y. Khatib,
- Ali Ait Hssain,
- Ali S. Omrani,
- Saad Al-Kaabi,
- Abdullatif Al Khal,
- Asmaa A. Al-Thani,
- Waseem Samsam,
- Abdulaziz Farooq,
- Jassim Al-Suwaidi,
- Mohammed Al-Maadheed,
- Heba H. Al-Siddiqi,
- Alexandra E. Butler,
- Julie V. Decock,
- Vidya Mohamed-Ali,
- Fares Al-Ejeh
Affiliations
- Maryam A. Y. Al-Nesf
- Department of Medicine, Hamad General Hospital, Hamad Medical Corporation
- Houari B. Abdesselem
- Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University, Qatar Foundation
- Ilham Bensmail
- Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University, Qatar Foundation
- Shahd Ibrahim
- Department of Medicine, Hamad General Hospital, Hamad Medical Corporation
- Walaa A. H. Saeed
- Department of Medicine, Hamad General Hospital, Hamad Medical Corporation
- Sara S. I. Mohammed
- Department of Medicine, Hamad General Hospital, Hamad Medical Corporation
- Almurtada Razok
- Department of Medicine, Hamad General Hospital, Hamad Medical Corporation
- Hashim Alhussain
- Biomedical Research Center, Qatar University
- Reham M. A. Aly
- Biomedical Research Center, Qatar University
- Muna Al Maslamani
- Communicable Disease Center (CDC) and the Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation
- Khalid Ouararhni
- Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University, Qatar Foundation
- Mohamad Y. Khatib
- Hezm Mebairek General Hospital, Hamad Medical Corporation
- Ali Ait Hssain
- Department of Medicine, Hamad General Hospital, Hamad Medical Corporation
- Ali S. Omrani
- Communicable Disease Center (CDC) and the Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation
- Saad Al-Kaabi
- Department of Medicine, Hamad General Hospital, Hamad Medical Corporation
- Abdullatif Al Khal
- Communicable Disease Center (CDC) and the Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation
- Asmaa A. Al-Thani
- Biomedical Research Center, Qatar University
- Waseem Samsam
- Anti-Doping Laboratory Qatar
- Abdulaziz Farooq
- Aspetar Hospital, Orthopaedic and Sports Medicine Hospital, FIFA Medical Centre of Excellence
- Jassim Al-Suwaidi
- Department of Medicine, Hamad General Hospital, Hamad Medical Corporation
- Mohammed Al-Maadheed
- Center of Metabolism and Inflammation, Division of Medicine, Royal Free Campus, University College London
- Heba H. Al-Siddiqi
- Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University, Qatar Foundation
- Alexandra E. Butler
- Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University, Qatar Foundation
- Julie V. Decock
- Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University, Qatar Foundation
- Vidya Mohamed-Ali
- Center of Metabolism and Inflammation, Division of Medicine, Royal Free Campus, University College London
- Fares Al-Ejeh
- Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University, Qatar Foundation
- DOI
- https://doi.org/10.1038/s41467-022-28639-4
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 14
Abstract
Prognostic markers for patients with COVID-19 are of critical importance in determining the course of SARS-CoV-2 infection and patient handling. Here the authors determine and apply a prognostic proteomic panel for risk and drug prediction in the management of SARS-CoV-2 infected patients.
